Ovarian Sertoli-Leydig Cell Tumors: Epidemiological, Clinical and Prognostic Factors
Abstract Objective To describe a series of cases of ovarian Sertoli-Leydig cell tumors (SLCTs). Methods Retrospective review of 12 cases of SLCT treated at the Hospital do Câncer de Barretos, Barretos, state of São Paulo, Brazil, between October 2009 and August 2017. Results The median age of...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Beatriz Guerreiro Ruiz Castro [verfasserIn] Cristiano de Pádua Souza [verfasserIn] Carlos Eduardo Mattos da Cunha Andrade [verfasserIn] Marcelo de Andrade Vieira [verfasserIn] Diocésio Alves Pinto de Andrade [verfasserIn] Ricardo dos Reis [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch ; Portugiesisch |
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Revista Brasileira de Ginecologia e Obstetrícia - Federação Brasileira das Sociedades de Ginecologia e Obstetrícia, 2004 |
|---|
| Links: |
Link aufrufen |
|---|
| DOI / URN: |
10.1055/s-0039-1693056 |
|---|
| Katalog-ID: |
DOAJ075923416 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ075923416 | ||
| 003 | DE-627 | ||
| 005 | 20230502114702.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230228nuuuuuuuuxx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1055/s-0039-1693056 |2 doi | |
| 035 | |a (DE-627)DOAJ075923416 | ||
| 035 | |a (DE-599)DOAJ170708c45d7f443991c97794c4eff975 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng |a por | ||
| 050 | 0 | |a RG1-991 | |
| 100 | 0 | |a Beatriz Guerreiro Ruiz Castro |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ovarian Sertoli-Leydig Cell Tumors: Epidemiological, Clinical and Prognostic Factors |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Objective To describe a series of cases of ovarian Sertoli-Leydig cell tumors (SLCTs). Methods Retrospective review of 12 cases of SLCT treated at the Hospital do Câncer de Barretos, Barretos, state of São Paulo, Brazil, between October 2009 and August 2017. Results The median age of the patients was 31 years old (15-71 years old). A total of 9 patients (75.0%) presented symptoms: 8 (66.7%) presented with abdominal pain, 5 (41.7%) presented with abdominal enlargement, 2 (16.7%) presentedwith virilizing signs, 2 (16.7%) presented with abnormal uterine bleeding, 1 (8.3%) presented with dyspareunia, and 1 (8.3%) presented with weight loss. The median preoperative lactate dehydrogenase (LDH) was 504.5 U/L (138-569 U/L), alpha-fetoprotein (AFP) was 2.0 ng/ml (1.1-11.3 ng/ml), human chorionic gonadotropin (β-hCG) was 0.6 mUI/ml (0.0-2.3 mUI/ml), carcinoembryonic antigen (CEA) was 0.9 ng/ml (0.7-3.4 ng/ml), and cancer antigen 125 (CA-125) was 26.0 U/ml (19.1-147.0 U/ml). All of the tumors were unilateral and surgically treated. Lymphadenectomy was performed in 3 (25.0%) patients, but none of the three patients submitted to lymphadenectomy presented lymph node involvement. In the anatomopathological exam, 1 (8.3%) tumor was well-differentiated, 8 (66.7%) were moderately differentiated, and 3 (25.0%) were poorly differentiated. A total of 5 (55.6%) tumors were solid-cystic, 2 (22.2%) were purely cystic, 1 (11.1%) was cystic with vegetations, and 1 (11.1%) was purely solid, but for 3 patients this information was not available. The median lesion size was 14.2 cm (3.2-23.5 cm). All of the tumors were at stage IA of the 2014 classification of the International Federation ofGynecology andObstetrics (FIGO). A total of 2 (16.7%) patients received adjuvant treatment; 1 of themunderwent 3 cycles of paclitaxel and carboplatin every 21days, and the other underwent 4 cycles of ifosfamide, cisplatin and etoposide every 21 days. None of all of the patients had recurrence, and one death related to complications after surgical staging occurred. Conclusion Abdominal pain was the most frequent presentation. There was no ultrasonographic pattern. All of the SLCTs were at stage IA, and most of them were moderately differentiated. Relapses did not occur, but one death related to the surgical staging occurred. | ||
| 650 | 4 | |a ovarian neoplasms | |
| 650 | 4 | |a Sertoli-Leydig cell tumor | |
| 650 | 4 | |a oncologic prognosis | |
| 653 | 0 | |a Gynecology and obstetrics | |
| 700 | 0 | |a Cristiano de Pádua Souza |e verfasserin |4 aut | |
| 700 | 0 | |a Carlos Eduardo Mattos da Cunha Andrade |e verfasserin |4 aut | |
| 700 | 0 | |a Marcelo de Andrade Vieira |e verfasserin |4 aut | |
| 700 | 0 | |a Diocésio Alves Pinto de Andrade |e verfasserin |4 aut | |
| 700 | 0 | |a Ricardo dos Reis |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Revista Brasileira de Ginecologia e Obstetrícia |d Federação Brasileira das Sociedades de Ginecologia e Obstetrícia, 2004 |w (DE-627)363749608 |w (DE-600)2105176-8 |x 01007203 |7 nnns |
| 856 | 4 | 0 | |u https://doi.org/10.1055/s-0039-1693056 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/170708c45d7f443991c97794c4eff975 |z kostenfrei |
| 856 | 4 | 0 | |u http://www.scielo.br/pdf/rbgo/v41n7/1806-9339-rbgo-41-07-440.pdf |z kostenfrei |
| 856 | 4 | 0 | |u http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-72032019000700440&tlng=en |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/0100-7203 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| author_variant |
b g r c bgrc c d p s cdps c e m d c a cemdca m d a v mdav d a p d a dapda r d r rdr |
|---|---|
| matchkey_str |
article:01007203:uuuuuuuu::vrasroiedgeluospdmooiaciiaa |
| callnumber-subject-code |
RG |
| allfields |
10.1055/s-0039-1693056 doi (DE-627)DOAJ075923416 (DE-599)DOAJ170708c45d7f443991c97794c4eff975 DE-627 ger DE-627 rakwb eng por RG1-991 Beatriz Guerreiro Ruiz Castro verfasserin aut Ovarian Sertoli-Leydig Cell Tumors: Epidemiological, Clinical and Prognostic Factors Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Objective To describe a series of cases of ovarian Sertoli-Leydig cell tumors (SLCTs). Methods Retrospective review of 12 cases of SLCT treated at the Hospital do Câncer de Barretos, Barretos, state of São Paulo, Brazil, between October 2009 and August 2017. Results The median age of the patients was 31 years old (15-71 years old). A total of 9 patients (75.0%) presented symptoms: 8 (66.7%) presented with abdominal pain, 5 (41.7%) presented with abdominal enlargement, 2 (16.7%) presentedwith virilizing signs, 2 (16.7%) presented with abnormal uterine bleeding, 1 (8.3%) presented with dyspareunia, and 1 (8.3%) presented with weight loss. The median preoperative lactate dehydrogenase (LDH) was 504.5 U/L (138-569 U/L), alpha-fetoprotein (AFP) was 2.0 ng/ml (1.1-11.3 ng/ml), human chorionic gonadotropin (β-hCG) was 0.6 mUI/ml (0.0-2.3 mUI/ml), carcinoembryonic antigen (CEA) was 0.9 ng/ml (0.7-3.4 ng/ml), and cancer antigen 125 (CA-125) was 26.0 U/ml (19.1-147.0 U/ml). All of the tumors were unilateral and surgically treated. Lymphadenectomy was performed in 3 (25.0%) patients, but none of the three patients submitted to lymphadenectomy presented lymph node involvement. In the anatomopathological exam, 1 (8.3%) tumor was well-differentiated, 8 (66.7%) were moderately differentiated, and 3 (25.0%) were poorly differentiated. A total of 5 (55.6%) tumors were solid-cystic, 2 (22.2%) were purely cystic, 1 (11.1%) was cystic with vegetations, and 1 (11.1%) was purely solid, but for 3 patients this information was not available. The median lesion size was 14.2 cm (3.2-23.5 cm). All of the tumors were at stage IA of the 2014 classification of the International Federation ofGynecology andObstetrics (FIGO). A total of 2 (16.7%) patients received adjuvant treatment; 1 of themunderwent 3 cycles of paclitaxel and carboplatin every 21days, and the other underwent 4 cycles of ifosfamide, cisplatin and etoposide every 21 days. None of all of the patients had recurrence, and one death related to complications after surgical staging occurred. Conclusion Abdominal pain was the most frequent presentation. There was no ultrasonographic pattern. All of the SLCTs were at stage IA, and most of them were moderately differentiated. Relapses did not occur, but one death related to the surgical staging occurred. ovarian neoplasms Sertoli-Leydig cell tumor oncologic prognosis Gynecology and obstetrics Cristiano de Pádua Souza verfasserin aut Carlos Eduardo Mattos da Cunha Andrade verfasserin aut Marcelo de Andrade Vieira verfasserin aut Diocésio Alves Pinto de Andrade verfasserin aut Ricardo dos Reis verfasserin aut In Revista Brasileira de Ginecologia e Obstetrícia Federação Brasileira das Sociedades de Ginecologia e Obstetrícia, 2004 (DE-627)363749608 (DE-600)2105176-8 01007203 nnns https://doi.org/10.1055/s-0039-1693056 kostenfrei https://doaj.org/article/170708c45d7f443991c97794c4eff975 kostenfrei http://www.scielo.br/pdf/rbgo/v41n7/1806-9339-rbgo-41-07-440.pdf kostenfrei http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-72032019000700440&tlng=en kostenfrei https://doaj.org/toc/0100-7203 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR |
| spelling |
10.1055/s-0039-1693056 doi (DE-627)DOAJ075923416 (DE-599)DOAJ170708c45d7f443991c97794c4eff975 DE-627 ger DE-627 rakwb eng por RG1-991 Beatriz Guerreiro Ruiz Castro verfasserin aut Ovarian Sertoli-Leydig Cell Tumors: Epidemiological, Clinical and Prognostic Factors Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Objective To describe a series of cases of ovarian Sertoli-Leydig cell tumors (SLCTs). Methods Retrospective review of 12 cases of SLCT treated at the Hospital do Câncer de Barretos, Barretos, state of São Paulo, Brazil, between October 2009 and August 2017. Results The median age of the patients was 31 years old (15-71 years old). A total of 9 patients (75.0%) presented symptoms: 8 (66.7%) presented with abdominal pain, 5 (41.7%) presented with abdominal enlargement, 2 (16.7%) presentedwith virilizing signs, 2 (16.7%) presented with abnormal uterine bleeding, 1 (8.3%) presented with dyspareunia, and 1 (8.3%) presented with weight loss. The median preoperative lactate dehydrogenase (LDH) was 504.5 U/L (138-569 U/L), alpha-fetoprotein (AFP) was 2.0 ng/ml (1.1-11.3 ng/ml), human chorionic gonadotropin (β-hCG) was 0.6 mUI/ml (0.0-2.3 mUI/ml), carcinoembryonic antigen (CEA) was 0.9 ng/ml (0.7-3.4 ng/ml), and cancer antigen 125 (CA-125) was 26.0 U/ml (19.1-147.0 U/ml). All of the tumors were unilateral and surgically treated. Lymphadenectomy was performed in 3 (25.0%) patients, but none of the three patients submitted to lymphadenectomy presented lymph node involvement. In the anatomopathological exam, 1 (8.3%) tumor was well-differentiated, 8 (66.7%) were moderately differentiated, and 3 (25.0%) were poorly differentiated. A total of 5 (55.6%) tumors were solid-cystic, 2 (22.2%) were purely cystic, 1 (11.1%) was cystic with vegetations, and 1 (11.1%) was purely solid, but for 3 patients this information was not available. The median lesion size was 14.2 cm (3.2-23.5 cm). All of the tumors were at stage IA of the 2014 classification of the International Federation ofGynecology andObstetrics (FIGO). A total of 2 (16.7%) patients received adjuvant treatment; 1 of themunderwent 3 cycles of paclitaxel and carboplatin every 21days, and the other underwent 4 cycles of ifosfamide, cisplatin and etoposide every 21 days. None of all of the patients had recurrence, and one death related to complications after surgical staging occurred. Conclusion Abdominal pain was the most frequent presentation. There was no ultrasonographic pattern. All of the SLCTs were at stage IA, and most of them were moderately differentiated. Relapses did not occur, but one death related to the surgical staging occurred. ovarian neoplasms Sertoli-Leydig cell tumor oncologic prognosis Gynecology and obstetrics Cristiano de Pádua Souza verfasserin aut Carlos Eduardo Mattos da Cunha Andrade verfasserin aut Marcelo de Andrade Vieira verfasserin aut Diocésio Alves Pinto de Andrade verfasserin aut Ricardo dos Reis verfasserin aut In Revista Brasileira de Ginecologia e Obstetrícia Federação Brasileira das Sociedades de Ginecologia e Obstetrícia, 2004 (DE-627)363749608 (DE-600)2105176-8 01007203 nnns https://doi.org/10.1055/s-0039-1693056 kostenfrei https://doaj.org/article/170708c45d7f443991c97794c4eff975 kostenfrei http://www.scielo.br/pdf/rbgo/v41n7/1806-9339-rbgo-41-07-440.pdf kostenfrei http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-72032019000700440&tlng=en kostenfrei https://doaj.org/toc/0100-7203 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR |
| allfields_unstemmed |
10.1055/s-0039-1693056 doi (DE-627)DOAJ075923416 (DE-599)DOAJ170708c45d7f443991c97794c4eff975 DE-627 ger DE-627 rakwb eng por RG1-991 Beatriz Guerreiro Ruiz Castro verfasserin aut Ovarian Sertoli-Leydig Cell Tumors: Epidemiological, Clinical and Prognostic Factors Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Objective To describe a series of cases of ovarian Sertoli-Leydig cell tumors (SLCTs). Methods Retrospective review of 12 cases of SLCT treated at the Hospital do Câncer de Barretos, Barretos, state of São Paulo, Brazil, between October 2009 and August 2017. Results The median age of the patients was 31 years old (15-71 years old). A total of 9 patients (75.0%) presented symptoms: 8 (66.7%) presented with abdominal pain, 5 (41.7%) presented with abdominal enlargement, 2 (16.7%) presentedwith virilizing signs, 2 (16.7%) presented with abnormal uterine bleeding, 1 (8.3%) presented with dyspareunia, and 1 (8.3%) presented with weight loss. The median preoperative lactate dehydrogenase (LDH) was 504.5 U/L (138-569 U/L), alpha-fetoprotein (AFP) was 2.0 ng/ml (1.1-11.3 ng/ml), human chorionic gonadotropin (β-hCG) was 0.6 mUI/ml (0.0-2.3 mUI/ml), carcinoembryonic antigen (CEA) was 0.9 ng/ml (0.7-3.4 ng/ml), and cancer antigen 125 (CA-125) was 26.0 U/ml (19.1-147.0 U/ml). All of the tumors were unilateral and surgically treated. Lymphadenectomy was performed in 3 (25.0%) patients, but none of the three patients submitted to lymphadenectomy presented lymph node involvement. In the anatomopathological exam, 1 (8.3%) tumor was well-differentiated, 8 (66.7%) were moderately differentiated, and 3 (25.0%) were poorly differentiated. A total of 5 (55.6%) tumors were solid-cystic, 2 (22.2%) were purely cystic, 1 (11.1%) was cystic with vegetations, and 1 (11.1%) was purely solid, but for 3 patients this information was not available. The median lesion size was 14.2 cm (3.2-23.5 cm). All of the tumors were at stage IA of the 2014 classification of the International Federation ofGynecology andObstetrics (FIGO). A total of 2 (16.7%) patients received adjuvant treatment; 1 of themunderwent 3 cycles of paclitaxel and carboplatin every 21days, and the other underwent 4 cycles of ifosfamide, cisplatin and etoposide every 21 days. None of all of the patients had recurrence, and one death related to complications after surgical staging occurred. Conclusion Abdominal pain was the most frequent presentation. There was no ultrasonographic pattern. All of the SLCTs were at stage IA, and most of them were moderately differentiated. Relapses did not occur, but one death related to the surgical staging occurred. ovarian neoplasms Sertoli-Leydig cell tumor oncologic prognosis Gynecology and obstetrics Cristiano de Pádua Souza verfasserin aut Carlos Eduardo Mattos da Cunha Andrade verfasserin aut Marcelo de Andrade Vieira verfasserin aut Diocésio Alves Pinto de Andrade verfasserin aut Ricardo dos Reis verfasserin aut In Revista Brasileira de Ginecologia e Obstetrícia Federação Brasileira das Sociedades de Ginecologia e Obstetrícia, 2004 (DE-627)363749608 (DE-600)2105176-8 01007203 nnns https://doi.org/10.1055/s-0039-1693056 kostenfrei https://doaj.org/article/170708c45d7f443991c97794c4eff975 kostenfrei http://www.scielo.br/pdf/rbgo/v41n7/1806-9339-rbgo-41-07-440.pdf kostenfrei http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-72032019000700440&tlng=en kostenfrei https://doaj.org/toc/0100-7203 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR |
| allfieldsGer |
10.1055/s-0039-1693056 doi (DE-627)DOAJ075923416 (DE-599)DOAJ170708c45d7f443991c97794c4eff975 DE-627 ger DE-627 rakwb eng por RG1-991 Beatriz Guerreiro Ruiz Castro verfasserin aut Ovarian Sertoli-Leydig Cell Tumors: Epidemiological, Clinical and Prognostic Factors Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Objective To describe a series of cases of ovarian Sertoli-Leydig cell tumors (SLCTs). Methods Retrospective review of 12 cases of SLCT treated at the Hospital do Câncer de Barretos, Barretos, state of São Paulo, Brazil, between October 2009 and August 2017. Results The median age of the patients was 31 years old (15-71 years old). A total of 9 patients (75.0%) presented symptoms: 8 (66.7%) presented with abdominal pain, 5 (41.7%) presented with abdominal enlargement, 2 (16.7%) presentedwith virilizing signs, 2 (16.7%) presented with abnormal uterine bleeding, 1 (8.3%) presented with dyspareunia, and 1 (8.3%) presented with weight loss. The median preoperative lactate dehydrogenase (LDH) was 504.5 U/L (138-569 U/L), alpha-fetoprotein (AFP) was 2.0 ng/ml (1.1-11.3 ng/ml), human chorionic gonadotropin (β-hCG) was 0.6 mUI/ml (0.0-2.3 mUI/ml), carcinoembryonic antigen (CEA) was 0.9 ng/ml (0.7-3.4 ng/ml), and cancer antigen 125 (CA-125) was 26.0 U/ml (19.1-147.0 U/ml). All of the tumors were unilateral and surgically treated. Lymphadenectomy was performed in 3 (25.0%) patients, but none of the three patients submitted to lymphadenectomy presented lymph node involvement. In the anatomopathological exam, 1 (8.3%) tumor was well-differentiated, 8 (66.7%) were moderately differentiated, and 3 (25.0%) were poorly differentiated. A total of 5 (55.6%) tumors were solid-cystic, 2 (22.2%) were purely cystic, 1 (11.1%) was cystic with vegetations, and 1 (11.1%) was purely solid, but for 3 patients this information was not available. The median lesion size was 14.2 cm (3.2-23.5 cm). All of the tumors were at stage IA of the 2014 classification of the International Federation ofGynecology andObstetrics (FIGO). A total of 2 (16.7%) patients received adjuvant treatment; 1 of themunderwent 3 cycles of paclitaxel and carboplatin every 21days, and the other underwent 4 cycles of ifosfamide, cisplatin and etoposide every 21 days. None of all of the patients had recurrence, and one death related to complications after surgical staging occurred. Conclusion Abdominal pain was the most frequent presentation. There was no ultrasonographic pattern. All of the SLCTs were at stage IA, and most of them were moderately differentiated. Relapses did not occur, but one death related to the surgical staging occurred. ovarian neoplasms Sertoli-Leydig cell tumor oncologic prognosis Gynecology and obstetrics Cristiano de Pádua Souza verfasserin aut Carlos Eduardo Mattos da Cunha Andrade verfasserin aut Marcelo de Andrade Vieira verfasserin aut Diocésio Alves Pinto de Andrade verfasserin aut Ricardo dos Reis verfasserin aut In Revista Brasileira de Ginecologia e Obstetrícia Federação Brasileira das Sociedades de Ginecologia e Obstetrícia, 2004 (DE-627)363749608 (DE-600)2105176-8 01007203 nnns https://doi.org/10.1055/s-0039-1693056 kostenfrei https://doaj.org/article/170708c45d7f443991c97794c4eff975 kostenfrei http://www.scielo.br/pdf/rbgo/v41n7/1806-9339-rbgo-41-07-440.pdf kostenfrei http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-72032019000700440&tlng=en kostenfrei https://doaj.org/toc/0100-7203 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR |
| allfieldsSound |
10.1055/s-0039-1693056 doi (DE-627)DOAJ075923416 (DE-599)DOAJ170708c45d7f443991c97794c4eff975 DE-627 ger DE-627 rakwb eng por RG1-991 Beatriz Guerreiro Ruiz Castro verfasserin aut Ovarian Sertoli-Leydig Cell Tumors: Epidemiological, Clinical and Prognostic Factors Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Objective To describe a series of cases of ovarian Sertoli-Leydig cell tumors (SLCTs). Methods Retrospective review of 12 cases of SLCT treated at the Hospital do Câncer de Barretos, Barretos, state of São Paulo, Brazil, between October 2009 and August 2017. Results The median age of the patients was 31 years old (15-71 years old). A total of 9 patients (75.0%) presented symptoms: 8 (66.7%) presented with abdominal pain, 5 (41.7%) presented with abdominal enlargement, 2 (16.7%) presentedwith virilizing signs, 2 (16.7%) presented with abnormal uterine bleeding, 1 (8.3%) presented with dyspareunia, and 1 (8.3%) presented with weight loss. The median preoperative lactate dehydrogenase (LDH) was 504.5 U/L (138-569 U/L), alpha-fetoprotein (AFP) was 2.0 ng/ml (1.1-11.3 ng/ml), human chorionic gonadotropin (β-hCG) was 0.6 mUI/ml (0.0-2.3 mUI/ml), carcinoembryonic antigen (CEA) was 0.9 ng/ml (0.7-3.4 ng/ml), and cancer antigen 125 (CA-125) was 26.0 U/ml (19.1-147.0 U/ml). All of the tumors were unilateral and surgically treated. Lymphadenectomy was performed in 3 (25.0%) patients, but none of the three patients submitted to lymphadenectomy presented lymph node involvement. In the anatomopathological exam, 1 (8.3%) tumor was well-differentiated, 8 (66.7%) were moderately differentiated, and 3 (25.0%) were poorly differentiated. A total of 5 (55.6%) tumors were solid-cystic, 2 (22.2%) were purely cystic, 1 (11.1%) was cystic with vegetations, and 1 (11.1%) was purely solid, but for 3 patients this information was not available. The median lesion size was 14.2 cm (3.2-23.5 cm). All of the tumors were at stage IA of the 2014 classification of the International Federation ofGynecology andObstetrics (FIGO). A total of 2 (16.7%) patients received adjuvant treatment; 1 of themunderwent 3 cycles of paclitaxel and carboplatin every 21days, and the other underwent 4 cycles of ifosfamide, cisplatin and etoposide every 21 days. None of all of the patients had recurrence, and one death related to complications after surgical staging occurred. Conclusion Abdominal pain was the most frequent presentation. There was no ultrasonographic pattern. All of the SLCTs were at stage IA, and most of them were moderately differentiated. Relapses did not occur, but one death related to the surgical staging occurred. ovarian neoplasms Sertoli-Leydig cell tumor oncologic prognosis Gynecology and obstetrics Cristiano de Pádua Souza verfasserin aut Carlos Eduardo Mattos da Cunha Andrade verfasserin aut Marcelo de Andrade Vieira verfasserin aut Diocésio Alves Pinto de Andrade verfasserin aut Ricardo dos Reis verfasserin aut In Revista Brasileira de Ginecologia e Obstetrícia Federação Brasileira das Sociedades de Ginecologia e Obstetrícia, 2004 (DE-627)363749608 (DE-600)2105176-8 01007203 nnns https://doi.org/10.1055/s-0039-1693056 kostenfrei https://doaj.org/article/170708c45d7f443991c97794c4eff975 kostenfrei http://www.scielo.br/pdf/rbgo/v41n7/1806-9339-rbgo-41-07-440.pdf kostenfrei http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-72032019000700440&tlng=en kostenfrei https://doaj.org/toc/0100-7203 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR |
| language |
English Portuguese |
| source |
In Revista Brasileira de Ginecologia e Obstetrícia |
| sourceStr |
In Revista Brasileira de Ginecologia e Obstetrícia |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
ovarian neoplasms Sertoli-Leydig cell tumor oncologic prognosis Gynecology and obstetrics |
| isfreeaccess_bool |
true |
| container_title |
Revista Brasileira de Ginecologia e Obstetrícia |
| authorswithroles_txt_mv |
Beatriz Guerreiro Ruiz Castro @@aut@@ Cristiano de Pádua Souza @@aut@@ Carlos Eduardo Mattos da Cunha Andrade @@aut@@ Marcelo de Andrade Vieira @@aut@@ Diocésio Alves Pinto de Andrade @@aut@@ Ricardo dos Reis @@aut@@ |
| publishDateDaySort_date |
2024-01-01T00:00:00Z |
| hierarchy_top_id |
363749608 |
| id |
DOAJ075923416 |
| language_de |
englisch portugiesisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ075923416</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230502114702.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228nuuuuuuuuxx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1055/s-0039-1693056</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ075923416</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ170708c45d7f443991c97794c4eff975</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield><subfield code="a">por</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RG1-991</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Beatriz Guerreiro Ruiz Castro</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Ovarian Sertoli-Leydig Cell Tumors: Epidemiological, Clinical and Prognostic Factors</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Objective To describe a series of cases of ovarian Sertoli-Leydig cell tumors (SLCTs). Methods Retrospective review of 12 cases of SLCT treated at the Hospital do Câncer de Barretos, Barretos, state of São Paulo, Brazil, between October 2009 and August 2017. Results The median age of the patients was 31 years old (15-71 years old). A total of 9 patients (75.0%) presented symptoms: 8 (66.7%) presented with abdominal pain, 5 (41.7%) presented with abdominal enlargement, 2 (16.7%) presentedwith virilizing signs, 2 (16.7%) presented with abnormal uterine bleeding, 1 (8.3%) presented with dyspareunia, and 1 (8.3%) presented with weight loss. The median preoperative lactate dehydrogenase (LDH) was 504.5 U/L (138-569 U/L), alpha-fetoprotein (AFP) was 2.0 ng/ml (1.1-11.3 ng/ml), human chorionic gonadotropin (β-hCG) was 0.6 mUI/ml (0.0-2.3 mUI/ml), carcinoembryonic antigen (CEA) was 0.9 ng/ml (0.7-3.4 ng/ml), and cancer antigen 125 (CA-125) was 26.0 U/ml (19.1-147.0 U/ml). All of the tumors were unilateral and surgically treated. Lymphadenectomy was performed in 3 (25.0%) patients, but none of the three patients submitted to lymphadenectomy presented lymph node involvement. In the anatomopathological exam, 1 (8.3%) tumor was well-differentiated, 8 (66.7%) were moderately differentiated, and 3 (25.0%) were poorly differentiated. A total of 5 (55.6%) tumors were solid-cystic, 2 (22.2%) were purely cystic, 1 (11.1%) was cystic with vegetations, and 1 (11.1%) was purely solid, but for 3 patients this information was not available. The median lesion size was 14.2 cm (3.2-23.5 cm). All of the tumors were at stage IA of the 2014 classification of the International Federation ofGynecology andObstetrics (FIGO). A total of 2 (16.7%) patients received adjuvant treatment; 1 of themunderwent 3 cycles of paclitaxel and carboplatin every 21days, and the other underwent 4 cycles of ifosfamide, cisplatin and etoposide every 21 days. None of all of the patients had recurrence, and one death related to complications after surgical staging occurred. Conclusion Abdominal pain was the most frequent presentation. There was no ultrasonographic pattern. All of the SLCTs were at stage IA, and most of them were moderately differentiated. Relapses did not occur, but one death related to the surgical staging occurred.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ovarian neoplasms</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Sertoli-Leydig cell tumor</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">oncologic prognosis</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Gynecology and obstetrics</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Cristiano de Pádua Souza</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Carlos Eduardo Mattos da Cunha Andrade</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Marcelo de Andrade Vieira</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Diocésio Alves Pinto de Andrade</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ricardo dos Reis</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Revista Brasileira de Ginecologia e Obstetrícia</subfield><subfield code="d">Federação Brasileira das Sociedades de Ginecologia e Obstetrícia, 2004</subfield><subfield code="w">(DE-627)363749608</subfield><subfield code="w">(DE-600)2105176-8</subfield><subfield code="x">01007203</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1055/s-0039-1693056</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/170708c45d7f443991c97794c4eff975</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.scielo.br/pdf/rbgo/v41n7/1806-9339-rbgo-41-07-440.pdf</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-72032019000700440&tlng=en</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/0100-7203</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield></record></collection>
|
| callnumber-first |
R - Medicine |
| author |
Beatriz Guerreiro Ruiz Castro |
| spellingShingle |
Beatriz Guerreiro Ruiz Castro misc RG1-991 misc ovarian neoplasms misc Sertoli-Leydig cell tumor misc oncologic prognosis misc Gynecology and obstetrics Ovarian Sertoli-Leydig Cell Tumors: Epidemiological, Clinical and Prognostic Factors |
| authorStr |
Beatriz Guerreiro Ruiz Castro |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)363749608 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| callnumber-label |
RG1-991 |
| illustrated |
Not Illustrated |
| issn |
01007203 |
| topic_title |
RG1-991 Ovarian Sertoli-Leydig Cell Tumors: Epidemiological, Clinical and Prognostic Factors ovarian neoplasms Sertoli-Leydig cell tumor oncologic prognosis |
| topic |
misc RG1-991 misc ovarian neoplasms misc Sertoli-Leydig cell tumor misc oncologic prognosis misc Gynecology and obstetrics |
| topic_unstemmed |
misc RG1-991 misc ovarian neoplasms misc Sertoli-Leydig cell tumor misc oncologic prognosis misc Gynecology and obstetrics |
| topic_browse |
misc RG1-991 misc ovarian neoplasms misc Sertoli-Leydig cell tumor misc oncologic prognosis misc Gynecology and obstetrics |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Revista Brasileira de Ginecologia e Obstetrícia |
| hierarchy_parent_id |
363749608 |
| hierarchy_top_title |
Revista Brasileira de Ginecologia e Obstetrícia |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)363749608 (DE-600)2105176-8 |
| title |
Ovarian Sertoli-Leydig Cell Tumors: Epidemiological, Clinical and Prognostic Factors |
| ctrlnum |
(DE-627)DOAJ075923416 (DE-599)DOAJ170708c45d7f443991c97794c4eff975 |
| title_full |
Ovarian Sertoli-Leydig Cell Tumors: Epidemiological, Clinical and Prognostic Factors |
| author_sort |
Beatriz Guerreiro Ruiz Castro |
| journal |
Revista Brasileira de Ginecologia e Obstetrícia |
| journalStr |
Revista Brasileira de Ginecologia e Obstetrícia |
| callnumber-first-code |
R |
| lang_code |
eng por |
| isOA_bool |
true |
| recordtype |
marc |
| contenttype_str_mv |
txt |
| author_browse |
Beatriz Guerreiro Ruiz Castro Cristiano de Pádua Souza Carlos Eduardo Mattos da Cunha Andrade Marcelo de Andrade Vieira Diocésio Alves Pinto de Andrade Ricardo dos Reis |
| class |
RG1-991 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Beatriz Guerreiro Ruiz Castro |
| doi_str_mv |
10.1055/s-0039-1693056 |
| author2-role |
verfasserin |
| title_sort |
ovarian sertoli-leydig cell tumors: epidemiological, clinical and prognostic factors |
| callnumber |
RG1-991 |
| title_auth |
Ovarian Sertoli-Leydig Cell Tumors: Epidemiological, Clinical and Prognostic Factors |
| abstract |
Abstract Objective To describe a series of cases of ovarian Sertoli-Leydig cell tumors (SLCTs). Methods Retrospective review of 12 cases of SLCT treated at the Hospital do Câncer de Barretos, Barretos, state of São Paulo, Brazil, between October 2009 and August 2017. Results The median age of the patients was 31 years old (15-71 years old). A total of 9 patients (75.0%) presented symptoms: 8 (66.7%) presented with abdominal pain, 5 (41.7%) presented with abdominal enlargement, 2 (16.7%) presentedwith virilizing signs, 2 (16.7%) presented with abnormal uterine bleeding, 1 (8.3%) presented with dyspareunia, and 1 (8.3%) presented with weight loss. The median preoperative lactate dehydrogenase (LDH) was 504.5 U/L (138-569 U/L), alpha-fetoprotein (AFP) was 2.0 ng/ml (1.1-11.3 ng/ml), human chorionic gonadotropin (β-hCG) was 0.6 mUI/ml (0.0-2.3 mUI/ml), carcinoembryonic antigen (CEA) was 0.9 ng/ml (0.7-3.4 ng/ml), and cancer antigen 125 (CA-125) was 26.0 U/ml (19.1-147.0 U/ml). All of the tumors were unilateral and surgically treated. Lymphadenectomy was performed in 3 (25.0%) patients, but none of the three patients submitted to lymphadenectomy presented lymph node involvement. In the anatomopathological exam, 1 (8.3%) tumor was well-differentiated, 8 (66.7%) were moderately differentiated, and 3 (25.0%) were poorly differentiated. A total of 5 (55.6%) tumors were solid-cystic, 2 (22.2%) were purely cystic, 1 (11.1%) was cystic with vegetations, and 1 (11.1%) was purely solid, but for 3 patients this information was not available. The median lesion size was 14.2 cm (3.2-23.5 cm). All of the tumors were at stage IA of the 2014 classification of the International Federation ofGynecology andObstetrics (FIGO). A total of 2 (16.7%) patients received adjuvant treatment; 1 of themunderwent 3 cycles of paclitaxel and carboplatin every 21days, and the other underwent 4 cycles of ifosfamide, cisplatin and etoposide every 21 days. None of all of the patients had recurrence, and one death related to complications after surgical staging occurred. Conclusion Abdominal pain was the most frequent presentation. There was no ultrasonographic pattern. All of the SLCTs were at stage IA, and most of them were moderately differentiated. Relapses did not occur, but one death related to the surgical staging occurred. |
| abstractGer |
Abstract Objective To describe a series of cases of ovarian Sertoli-Leydig cell tumors (SLCTs). Methods Retrospective review of 12 cases of SLCT treated at the Hospital do Câncer de Barretos, Barretos, state of São Paulo, Brazil, between October 2009 and August 2017. Results The median age of the patients was 31 years old (15-71 years old). A total of 9 patients (75.0%) presented symptoms: 8 (66.7%) presented with abdominal pain, 5 (41.7%) presented with abdominal enlargement, 2 (16.7%) presentedwith virilizing signs, 2 (16.7%) presented with abnormal uterine bleeding, 1 (8.3%) presented with dyspareunia, and 1 (8.3%) presented with weight loss. The median preoperative lactate dehydrogenase (LDH) was 504.5 U/L (138-569 U/L), alpha-fetoprotein (AFP) was 2.0 ng/ml (1.1-11.3 ng/ml), human chorionic gonadotropin (β-hCG) was 0.6 mUI/ml (0.0-2.3 mUI/ml), carcinoembryonic antigen (CEA) was 0.9 ng/ml (0.7-3.4 ng/ml), and cancer antigen 125 (CA-125) was 26.0 U/ml (19.1-147.0 U/ml). All of the tumors were unilateral and surgically treated. Lymphadenectomy was performed in 3 (25.0%) patients, but none of the three patients submitted to lymphadenectomy presented lymph node involvement. In the anatomopathological exam, 1 (8.3%) tumor was well-differentiated, 8 (66.7%) were moderately differentiated, and 3 (25.0%) were poorly differentiated. A total of 5 (55.6%) tumors were solid-cystic, 2 (22.2%) were purely cystic, 1 (11.1%) was cystic with vegetations, and 1 (11.1%) was purely solid, but for 3 patients this information was not available. The median lesion size was 14.2 cm (3.2-23.5 cm). All of the tumors were at stage IA of the 2014 classification of the International Federation ofGynecology andObstetrics (FIGO). A total of 2 (16.7%) patients received adjuvant treatment; 1 of themunderwent 3 cycles of paclitaxel and carboplatin every 21days, and the other underwent 4 cycles of ifosfamide, cisplatin and etoposide every 21 days. None of all of the patients had recurrence, and one death related to complications after surgical staging occurred. Conclusion Abdominal pain was the most frequent presentation. There was no ultrasonographic pattern. All of the SLCTs were at stage IA, and most of them were moderately differentiated. Relapses did not occur, but one death related to the surgical staging occurred. |
| abstract_unstemmed |
Abstract Objective To describe a series of cases of ovarian Sertoli-Leydig cell tumors (SLCTs). Methods Retrospective review of 12 cases of SLCT treated at the Hospital do Câncer de Barretos, Barretos, state of São Paulo, Brazil, between October 2009 and August 2017. Results The median age of the patients was 31 years old (15-71 years old). A total of 9 patients (75.0%) presented symptoms: 8 (66.7%) presented with abdominal pain, 5 (41.7%) presented with abdominal enlargement, 2 (16.7%) presentedwith virilizing signs, 2 (16.7%) presented with abnormal uterine bleeding, 1 (8.3%) presented with dyspareunia, and 1 (8.3%) presented with weight loss. The median preoperative lactate dehydrogenase (LDH) was 504.5 U/L (138-569 U/L), alpha-fetoprotein (AFP) was 2.0 ng/ml (1.1-11.3 ng/ml), human chorionic gonadotropin (β-hCG) was 0.6 mUI/ml (0.0-2.3 mUI/ml), carcinoembryonic antigen (CEA) was 0.9 ng/ml (0.7-3.4 ng/ml), and cancer antigen 125 (CA-125) was 26.0 U/ml (19.1-147.0 U/ml). All of the tumors were unilateral and surgically treated. Lymphadenectomy was performed in 3 (25.0%) patients, but none of the three patients submitted to lymphadenectomy presented lymph node involvement. In the anatomopathological exam, 1 (8.3%) tumor was well-differentiated, 8 (66.7%) were moderately differentiated, and 3 (25.0%) were poorly differentiated. A total of 5 (55.6%) tumors were solid-cystic, 2 (22.2%) were purely cystic, 1 (11.1%) was cystic with vegetations, and 1 (11.1%) was purely solid, but for 3 patients this information was not available. The median lesion size was 14.2 cm (3.2-23.5 cm). All of the tumors were at stage IA of the 2014 classification of the International Federation ofGynecology andObstetrics (FIGO). A total of 2 (16.7%) patients received adjuvant treatment; 1 of themunderwent 3 cycles of paclitaxel and carboplatin every 21days, and the other underwent 4 cycles of ifosfamide, cisplatin and etoposide every 21 days. None of all of the patients had recurrence, and one death related to complications after surgical staging occurred. Conclusion Abdominal pain was the most frequent presentation. There was no ultrasonographic pattern. All of the SLCTs were at stage IA, and most of them were moderately differentiated. Relapses did not occur, but one death related to the surgical staging occurred. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA |
| title_short |
Ovarian Sertoli-Leydig Cell Tumors: Epidemiological, Clinical and Prognostic Factors |
| url |
https://doi.org/10.1055/s-0039-1693056 https://doaj.org/article/170708c45d7f443991c97794c4eff975 http://www.scielo.br/pdf/rbgo/v41n7/1806-9339-rbgo-41-07-440.pdf http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-72032019000700440&tlng=en https://doaj.org/toc/0100-7203 |
| remote_bool |
true |
| author2 |
Cristiano de Pádua Souza Carlos Eduardo Mattos da Cunha Andrade Marcelo de Andrade Vieira Diocésio Alves Pinto de Andrade Ricardo dos Reis |
| author2Str |
Cristiano de Pádua Souza Carlos Eduardo Mattos da Cunha Andrade Marcelo de Andrade Vieira Diocésio Alves Pinto de Andrade Ricardo dos Reis |
| ppnlink |
363749608 |
| callnumber-subject |
RG - Gynecology and Obstetrics |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.1055/s-0039-1693056 |
| callnumber-a |
RG1-991 |
| up_date |
2024-07-03T17:36:17.463Z |
| _version_ |
1803580266213539840 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ075923416</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230502114702.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228nuuuuuuuuxx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1055/s-0039-1693056</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ075923416</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ170708c45d7f443991c97794c4eff975</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield><subfield code="a">por</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RG1-991</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Beatriz Guerreiro Ruiz Castro</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Ovarian Sertoli-Leydig Cell Tumors: Epidemiological, Clinical and Prognostic Factors</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Objective To describe a series of cases of ovarian Sertoli-Leydig cell tumors (SLCTs). Methods Retrospective review of 12 cases of SLCT treated at the Hospital do Câncer de Barretos, Barretos, state of São Paulo, Brazil, between October 2009 and August 2017. Results The median age of the patients was 31 years old (15-71 years old). A total of 9 patients (75.0%) presented symptoms: 8 (66.7%) presented with abdominal pain, 5 (41.7%) presented with abdominal enlargement, 2 (16.7%) presentedwith virilizing signs, 2 (16.7%) presented with abnormal uterine bleeding, 1 (8.3%) presented with dyspareunia, and 1 (8.3%) presented with weight loss. The median preoperative lactate dehydrogenase (LDH) was 504.5 U/L (138-569 U/L), alpha-fetoprotein (AFP) was 2.0 ng/ml (1.1-11.3 ng/ml), human chorionic gonadotropin (β-hCG) was 0.6 mUI/ml (0.0-2.3 mUI/ml), carcinoembryonic antigen (CEA) was 0.9 ng/ml (0.7-3.4 ng/ml), and cancer antigen 125 (CA-125) was 26.0 U/ml (19.1-147.0 U/ml). All of the tumors were unilateral and surgically treated. Lymphadenectomy was performed in 3 (25.0%) patients, but none of the three patients submitted to lymphadenectomy presented lymph node involvement. In the anatomopathological exam, 1 (8.3%) tumor was well-differentiated, 8 (66.7%) were moderately differentiated, and 3 (25.0%) were poorly differentiated. A total of 5 (55.6%) tumors were solid-cystic, 2 (22.2%) were purely cystic, 1 (11.1%) was cystic with vegetations, and 1 (11.1%) was purely solid, but for 3 patients this information was not available. The median lesion size was 14.2 cm (3.2-23.5 cm). All of the tumors were at stage IA of the 2014 classification of the International Federation ofGynecology andObstetrics (FIGO). A total of 2 (16.7%) patients received adjuvant treatment; 1 of themunderwent 3 cycles of paclitaxel and carboplatin every 21days, and the other underwent 4 cycles of ifosfamide, cisplatin and etoposide every 21 days. None of all of the patients had recurrence, and one death related to complications after surgical staging occurred. Conclusion Abdominal pain was the most frequent presentation. There was no ultrasonographic pattern. All of the SLCTs were at stage IA, and most of them were moderately differentiated. Relapses did not occur, but one death related to the surgical staging occurred.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ovarian neoplasms</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Sertoli-Leydig cell tumor</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">oncologic prognosis</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Gynecology and obstetrics</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Cristiano de Pádua Souza</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Carlos Eduardo Mattos da Cunha Andrade</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Marcelo de Andrade Vieira</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Diocésio Alves Pinto de Andrade</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ricardo dos Reis</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Revista Brasileira de Ginecologia e Obstetrícia</subfield><subfield code="d">Federação Brasileira das Sociedades de Ginecologia e Obstetrícia, 2004</subfield><subfield code="w">(DE-627)363749608</subfield><subfield code="w">(DE-600)2105176-8</subfield><subfield code="x">01007203</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1055/s-0039-1693056</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/170708c45d7f443991c97794c4eff975</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.scielo.br/pdf/rbgo/v41n7/1806-9339-rbgo-41-07-440.pdf</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-72032019000700440&tlng=en</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/0100-7203</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield></record></collection>
|
| score |
7.3985815 |